Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Anderson H and Hopwood P (2000) Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomised trial with quality of life as the primary outcome. Br J Cancer 83: 447–453
Bakowski MT and Crouch JC (1983) Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer Treat Rev 10: 159–172
Berthelot JM, Will BP, Evans WK, Coyle D, Earle CC and Bordeleau L (2000) Decision framework for chemotherapeutic interventions for metastatic non-small cell lung cancer. J Natl Cancer Inst 92: 1321–1329
Bonomi P, Kim K and Fairclough D (2000) Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623–631
Bunn PA (1996) New drug combinations in the treatment of advanced non-small cell (NSCLC) and small cell (SCLC) lung cancer. American Society of Clinical Oncology educational book, 204
Cullen MH and Woodroffe CM (1999) Mitomycin, ifosfamide and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J Clin Oncol 17: 3188–3194
Donnelly S and Walsh D (1996) Quality of life assessment in advanced cancer. Palliat Med 10: 275–283
Ellis PA, Smith IE, Hardy JR, Nicolson MC, Talbot DC, Ashley SE and Pricst K (1995) Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. Br J Cancer 71: 366–370
Evans WK, Kocha W, Gagliardi A, Eady A and Newman TE (1999) The use of gemcitabine in non-small cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group. Cancer Prev Contrl 3: 84–94
Giaccone G, Splinter TA and Debruyne C (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. The European Organization for Research and Treatment of Cancer, Lung Cancer Cooperative Group. J Clin Oncol 16: 2133–2141
Jaakkimainen L, Goodwin PJ, Pater J, Warde P, Murray N and Rapp E for the NCI clinical trials group (1990) Counting the costs of chemotherapy in randomised trials in non-small cell lung cancer. J Clin Oncol 8: 1301–1309
Le Chevalier T, Brisgand D and Pujol JL (1996) Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer. Bull Cancer 83: 385–394
Luedke DW, Einhorn L, Omura GA, Sarma PR, Bartolucci AA, Birch R and Greco FA (1990) Randomized comparison of two combination regimens versus minimal chemotherapy in non-small cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol 8: 886–891
Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311: 899–909
Rosell R, Gomez-Codina J and Camps C (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. New Eng J Med 330: 153–158
Roth JA, Fossell F and Komaki R (1994) A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 86: 673–680
Sculier JP, Ghisdal L and Berghamans T (2001) The role of Mitomycin C in the treatment of Non-Small Cell Lung Cancer: A systemic review with meta-analysis of the literature. Br J Cancer,
Wozniak AJ, Crowley JJ and Balcerzak SP (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16: 2459–2465
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Bahl, A., Falk, S. Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know?. Br J Cancer 84, 1143–1145 (2001). https://doi.org/10.1054/bjoc.2000.1740
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1740
This article is cited by
-
Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities
Acta Pharmacologica Sinica (2017)
-
Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy
Scientific Reports (2017)
-
Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advanced North Indian lung cancer patients treated with platinum-based doublet chemotherapy
Medical Oncology (2017)
-
Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer
Scientific Reports (2015)
-
Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy
Scientific Reports (2015)